University Hospitals Cleveland Medical Center
University Hospitals Cleveland Medical Center was paid $76.72M by Medicaid between Jan 2018 and Dec 2024, across 328 billing codes. Its largest line is 99283, emergency room visit (moderate) — 14% of everything it billed.
CLEVELAND, OH 44106
Next to other Children's Hospital providers in Ohio
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 84,871 | $6.94M | |
| 2019 | 104,756 | $9.01M | |
| 2020 | 66,968 | $6.77M | |
| 2021 | 84,736 | $8.76M | |
| 2022 | 93,833 | $8.81M | |
| 2023 | 239,760 | $21.41M | |
| 2024incomplete | 195,959 | $15.02M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 68,860 | 65,029 | $10.76M |
| 41899 | Unlisted procedure, dentoalveolar structures | 8.6% | 6,606 | 5,816 | $6.63M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.1% | 36,935 | 34,079 | $5.45M |
| D2930 | Prefabricated stainless steel crown - primary tooth | 6.8% | 9,953 | 2,957 | $5.19M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.5% | 35,955 | 33,324 | $4.97M |
| 96127 | 4.8% | 28,147 | 20,916 | $3.69M | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.7% | 24,888 | 24,007 | $3.61M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 4.6% | 28,812 | 26,323 | $3.51M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.6% | 15,723 | 14,544 | $2.73M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 3.1% | 20,310 | 18,887 | $2.41M |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 2.5% | 7,145 | 5,208 | $1.88M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 2.2% | 14,691 | 13,594 | $1.73M |
316 more codes
| 99215 | Doctor's office visit, returning patient (complex) | 2.2% | 10,259 | $1.71M |
| D7140 | Extraction, erupted tooth or exposed root | 2.1% | 6,924 | $1.64M |
| 92551 | 2.1% | 18,686 | $1.63M | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.9% | 999 | $1.44M |
| D1351 | Sealant - per tooth | 1.7% | 2,567 | $1.30M |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.3% | 8,089 | $984K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.2% | 1,520 | $929K |
| 99285 | Emergency room visit (most serious) | 1.0% | 4,506 | $804K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.0% | 560 | $800K |
| D2330 | <1% | 1,376 | $762K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 4,832 | $747K |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 1,521 | $716K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,153 | $603K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,492 | $588K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,217 | $561K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 1,221 | $547K |
| G0378 | Hospital observation service, per hour | <1% | 5,530 | $460K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 256 | $442K |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 911 | $417K |
| 93325 | <1% | 2,705 | $387K | |
| 95716 | <1% | 338 | $365K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 843 | $340K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,013 | $306K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 624 | $291K |
| 42830 | <1% | 171 | $290K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,939 | $275K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,091 | $271K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 282 | $217K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 260 | $160K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 284 | $145K |
| 94010 | <1% | 2,320 | $144K | |
| 36430 | <1% | 609 | $142K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,936 | $142K |
| 01922 | <1% | 650 | $131K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 1,148 | $128K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 43,800 | $125K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 924 | $124K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,587 | $123K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 6,082 | $119K |
| 90670 | <1% | 15,074 | $118K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 1,795 | $103K |
| 90648 | <1% | 18,560 | $90K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 769 | $88K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,737 | $82K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 734 | $70K |
| 12011 | <1% | 308 | $64K | |
| 95700 | <1% | 366 | $64K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 119 | $61K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 463 | $59K |
| 76000 | <1% | 406 | $58K | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 984 | $58K |
| 96415 | <1% | 117 | $58K | |
| 87631 | <1% | 515 | $56K | |
| 59025 | Fetal non-stress test | <1% | 232 | $52K |
| 12001 | <1% | 231 | $50K | |
| 86850 | <1% | 1,772 | $48K | |
| 76825 | <1% | 838 | $48K | |
| 80069 | <1% | 3,500 | $47K | |
| 90686 | <1% | 13,043 | $46K | |
| D2331 | <1% | 126 | $45K | |
| 90633 | <1% | 7,838 | $45K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 164 | $43K |
| D2934 | <1% | 115 | $41K | |
| 92060 | <1% | 617 | $40K | |
| 82728 | <1% | 2,366 | $39K | |
| 90723 | <1% | 14,366 | $39K | |
| 80053 | Comprehensive metabolic panel | <1% | 5,658 | $37K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,877 | $34K |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 110 | $33K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,686 | $33K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,354 | $32K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 1,154 | $31K |
| 76827 | <1% | 1,025 | $31K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,442 | $30K |
| 83021 | <1% | 1,422 | $28K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 27,525 | $26K |
| 74018 | <1% | 1,246 | $26K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 115 | $25K |
| 86900 | <1% | 1,797 | $25K | |
| 85045 | <1% | 5,176 | $24K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,117 | $23K |
| 82805 | <1% | 538 | $23K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 51 | $23K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 136 | $22K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,619 | $21K |
| 90681 | <1% | 4,431 | $20K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 647 | $20K |
| 93320 | <1% | 1,173 | $19K | |
| 92552 | <1% | 168 | $19K | |
| 94060 | <1% | 177 | $18K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 8,246 | $17K |
| 82248 | <1% | 3,693 | $16K | |
| 90649 | <1% | 3,809 | $16K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 4,876 | $15K |
| 90696 | <1% | 4,431 | $14K | |
| 90710 | <1% | 3,471 | $13K | |
| 90716 | <1% | 2,645 | $12K | |
| 86920 | <1% | 325 | $12K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 630 | $12K |
| 92587 | <1% | 136 | $12K | |
| 86140 | <1% | 2,718 | $12K | |
| 87634 | <1% | 2,389 | $11K | |
| 90651 | <1% | 1,150 | $11K | |
| 90734 | <1% | 2,945 | $10K | |
| 71045 | Radiologic examination, chest; single view | <1% | 848 | $10K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,261 | $10K |
| 82247 | <1% | 1,889 | $9K | |
| 99384 | <1% | 124 | $9K | |
| 90677 | <1% | 2,390 | $9K | |
| J3490 | Unclassified drugs | <1% | 2,266 | $9K |
| 90715 | <1% | 2,033 | $9K | |
| 83615 | <1% | 1,455 | $8K | |
| 90620 | <1% | 1,333 | $8K | |
| 90707 | <1% | 2,632 | $8K | |
| 86901 | <1% | 1,797 | $8K | |
| 90680 | <1% | 1,946 | $8K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,232 | $8K |
| 90700 | <1% | 1,267 | $8K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 407 | $7K |
| 82947 | <1% | 2,339 | $7K | |
| 80076 | <1% | 457 | $7K | |
| 82570 | <1% | 1,029 | $7K | |
| 84450 | <1% | 2,126 | $7K | |
| 82977 | <1% | 1,007 | $6K | |
| 84460 | <1% | 2,125 | $6K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 33 | $6K |
| 73090 | <1% | 682 | $6K | |
| 85027 | <1% | 1,737 | $5K | |
| 90656 | <1% | 876 | $5K | |
| 00731 | <1% | 1,007 | $5K | |
| 93017 | <1% | 34 | $5K | |
| 12002 | <1% | 18 | $5K | |
| 96376 | <1% | 648 | $5K | |
| D1120 | Dental cleaning, child | <1% | 3,361 | $5K |
| 83540 | <1% | 694 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,189 | $5K |
| 36591 | <1% | 217 | $5K | |
| 81001 | <1% | 2,345 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 988 | $5K |
| 73130 | <1% | 766 | $5K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 816 | $5K |
| 83735 | <1% | 1,129 | $5K | |
| 81003 | <1% | 1,855 | $5K | |
| 96112 | <1% | 18 | $5K | |
| 76770 | <1% | 17 | $5K | |
| 90474 | <1% | 4,758 | $4K | |
| 92567 | <1% | 162 | $4K | |
| 73610 | <1% | 624 | $4K | |
| 84075 | <1% | 1,688 | $4K | |
| 84155 | <1% | 1,702 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 984 | $4K |
| 85007 | <1% | 847 | $4K | |
| 83550 | <1% | 685 | $4K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,133 | $4K |
| 73630 | <1% | 613 | $4K | |
| 84100 | <1% | 1,540 | $4K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 580 | $4K |
| 99383 | <1% | 40 | $4K | |
| 73590 | <1% | 463 | $4K | |
| 96367 | <1% | 41 | $4K | |
| 73560 | <1% | 495 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,284 | $3K |
| 73110 | <1% | 550 | $3K | |
| 43762 | <1% | 12 | $3K | |
| 82043 | <1% | 601 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,256 | $3K |
| Q2036 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) | <1% | 1,043 | $3K |
| 82330 | <1% | 668 | $3K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 21 | $3K |
| 87800 | <1% | 754 | $3K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,141 | $3K |
| 94664 | <1% | 196 | $3K | |
| 93975 | <1% | 12 | $2K | |
| 74019 | <1% | 179 | $2K | |
| 93225 | <1% | 31 | $2K | |
| 73070 | <1% | 281 | $2K | |
| 84439 | <1% | 182 | $2K | |
| 81025 | <1% | 2,378 | $2K | |
| 87070 | <1% | 797 | $2K | |
| 85610 | <1% | 658 | $2K | |
| 88720 | <1% | 5,196 | $2K | |
| 87040 | <1% | 561 | $2K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 293 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,569 | $2K |
| 80320 | <1% | 45 | $2K | |
| 92557 | <1% | 30 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 11,252 | $1K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 18 | $1K |
| 83690 | <1% | 1,012 | $1K | |
| 73080 | <1% | 124 | $1K | |
| 94621 | <1% | 13 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,934 | $1K |
| 99381 | <1% | 14 | $1K | |
| 83605 | <1% | 585 | $1K | |
| 87205 | <1% | 541 | $1K | |
| 82784 | <1% | 357 | $1K | |
| 00813 | <1% | 271 | $1K | |
| 73060 | <1% | 156 | $1K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 1,734 | $1K |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 1,603 | $1K |
| 81002 | <1% | 944 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 11,389 | $1K |
| 86780 | <1% | 270 | $1K | |
| 93226 | <1% | 31 | $1K | |
| 85730 | <1% | 651 | $1K | |
| 73030 | <1% | 161 | $954.57 | |
| 85018 | <1% | 467 | $949.88 | |
| 87186 | <1% | 474 | $925.98 | |
| 87075 | <1% | 673 | $915.92 | |
| 29125 | <1% | 87 | $904.52 | |
| 82435 | <1% | 458 | $888.80 | |
| 99401 | <1% | 17 | $870.09 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,885 | $869.95 |
| 87077 | <1% | 330 | $852.06 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 1,283 | $801.05 |
| 85652 | <1% | 1,523 | $795.40 | |
| 84132 | <1% | 492 | $697.12 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 683 | $668.51 |
| 86902 | <1% | 23 | $655.90 | |
| 88184 | <1% | 15 | $637.13 | |
| 69200 | <1% | 46 | $631.71 | |
| 69210 | <1% | 439 | $624.59 | |
| 73140 | <1% | 66 | $610.74 | |
| 80143 | <1% | 188 | $599.81 | |
| 84295 | <1% | 462 | $588.98 | |
| 85246 | <1% | 14 | $561.81 | |
| 00300 | <1% | 123 | $561.39 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 168 | $516.56 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 265 | $504.09 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 46 | $503.22 |
| 82077 | <1% | 119 | $459.22 | |
| 90671 | <1% | 1,097 | $458.60 | |
| 84156 | <1% | 262 | $423.95 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,439 | $422.15 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 54 | $397.11 |
| 86703 | <1% | 58 | $374.69 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,589 | $338.26 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,301 | $332.49 |
| 73552 | <1% | 109 | $308.54 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,306 | $295.22 |
| 80179 | <1% | 168 | $266.65 | |
| 72170 | <1% | 78 | $252.07 | |
| 92652 | <1% | 12 | $234.12 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,221 | $229.51 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,226 | $220.74 |
| 82150 | <1% | 158 | $216.76 | |
| A4217 | Sterile water/saline, 500 ml | <1% | 766 | $212.80 |
| 87799 | <1% | 16 | $202.93 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,100 | $191.84 |
| 82785 | <1% | 31 | $190.68 | |
| 87081 | <1% | 38 | $190.35 | |
| 84702 | <1% | 29 | $178.28 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,568 | $170.58 |
| 84550 | <1% | 35 | $170.53 | |
| 36406 | <1% | 52 | $165.88 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,210 | $160.21 |
| 90688 | <1% | 18 | $150.87 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,774 | $143.97 |
| D0272 | Bitewings - two radiographic images | <1% | 964 | $131.15 |
| 87102 | <1% | 92 | $117.13 | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 20 | $97.88 |
| 31720 | <1% | 644 | $94.62 | |
| 99417 | Prolong home eval add 15m | <1% | 489 | $78.83 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 151 | $77.40 |
| 82550 | <1% | 16 | $63.93 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 262 | $60.17 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,317 | $59.61 |
| 90461 | <1% | 359 | $48.63 | |
| 87206 | <1% | 28 | $45.34 | |
| 90480 | <1% | 313 | $42.00 | |
| 82962 | <1% | 19 | $37.97 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 550 | $37.83 |
| 85660 | <1% | 22 | $37.56 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 249 | $34.40 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 429 | $25.60 |
| 87210 | <1% | 14 | $20.13 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 49 | $16.68 |
| J7699 | Noc drugs, inhalation solution administered through dme | <1% | 52 | $15.41 |
| 91318 | <1% | 76 | $10.50 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 77 | $6.90 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 47 | $5.24 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 299 | $3.62 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 94 | $1.23 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 261 | $0.86 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 101 | $0.36 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 29 | $0.25 |
| 00840 | 0% | 28 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 78 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 525 | $0.00 |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | 0% | 57 | $0.00 |
| D0220 | Intraoral - periapical first radiographic image | 0% | 93 | $0.00 |
| 91320 | 0% | 63 | $0.00 | |
| 00920 | 0% | 14 | $0.00 | |
| D1110 | Prophylaxis - adult | 0% | 13 | $0.00 |
| D9230 | Inhalation of nitrous oxide / analgesia, anxiolysis | 0% | 38 | $0.00 |
| 00140 | 0% | 14 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 14 | $0.00 |
| D0330 | Panoramic radiographic image | 0% | 14 | $0.00 |
| 76377 | 0% | 38 | $0.00 | |
| 87116 | 0% | 13 | $0.00 | |
| D1310 | 0% | 147 | $0.00 | |
| L8699 | Prosthetic implant, not otherwise specified | 0% | 234 | $0.00 |
| D0150 | Comprehensive oral evaluation - new or established patient | 0% | 89 | $0.00 |
| D0240 | 0% | 224 | $0.00 | |
| 00126 | 0% | 312 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 819 | $0.00 |
| 94760 | 0% | 233 | $0.00 | |
| D0603 | 0% | 154 | $0.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 15 | $0.00 |
| D0120 | Dental checkup, returning patient | 0% | 68 | $0.00 |
| C1769 | Guide wire | 0% | 38 | $0.00 |
| D1206 | Topical application of fluoride varnish | 0% | 143 | $0.00 |
| 87015 | 0% | 13 | $0.00 | |
| D1330 | 0% | 146 | $0.00 | |
| 91319 | 0% | 64 | $0.00 | |
| D0140 | Limited oral evaluation - problem focused | 0% | 39 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.